HTGC - Hercules Capital, Inc.

NYSE - NYSE Delayed Price. Currency in USD
14.41
+0.04 (+0.28%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close14.37
Open14.41
Bid14.40 x 1000
Ask14.41 x 1200
Day's Range14.38 - 14.47
52 Week Range11.94 - 14.53
Volume416,542
Avg. Volume502,488
Market Cap1.508B
Beta (5Y Monthly)0.87
PE Ratio (TTM)12.77
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.28 (8.91%)
Ex-Dividend DateNov. 05, 2019
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    Hercules Capital Reaches $10.0 Billion Milestone in Total Debt Commitments Since Inception

    Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has originated more than $10.0 billion in total debt commitments since the Company’s inception in December 2003.

  • GlobeNewswire

    ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital

    ChemoCentryx, Inc., (CCXI) today announced that the Company has secured a credit facility of up to $100 million provided by Hercules Capital, Inc. (HTGC), a leader in customized financing for companies in life sciences and technology-related markets. “Through this non-dilutive credit mechanism, we have options to strengthen our robust balance sheet as we advance avacopan towards commercialization in ANCA vasculitis,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. The $100 million credit facility from Hercules Capital comprises three tranches over the next two years to be drawn at ChemoCentryx’s discretion as follows: the first tranche of $40 million is available through December 2020, $20 million of which would be available upon the submission of the avacopan New Drug Application (NDA) for the treatment of ANCA vasculitis; the second tranche of $30 million is available through December 2021 upon NDA approval of avacopan for the treatment of ANCA vasculitis (NDA Approval); the remaining $30 million is available through December 2022, subject to certain conditions.

  • Business Wire

    Hercules Capital Highlights 2019 Achievements, Setting a New Investment Record with $1.47 Billion in Total New Debt and Equity Commitments

    Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest specialty financing provider to innovative venture, growth and established stage companies backed by top-tier venture capital and select private equity firms, today announced select investment milestones and operating highlights for 2019.

  • GlobeNewswire

    Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions

    Low-interest (3-month LIBOR plus 3%) loan facility from Sumitomo Dainippon Pharma increased to allow repayment of pre-existing debtHiroshi Nomura, President, CEO, and.

  • Business Wire

    Hercules Capital Reports Third Quarter 2019 Financial Results

    Achieved Record Net Investment Income of $38.9 Million, or $0.37 per Share, which provides 116% Coverage of Base Distribution Payout

  • Business Wire

    Hercules Capital Announces Supplemental Cash Distribution of $0.03 per Share for the Third Quarter of 2019

    Hercules Capital, Inc. (HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a supplemental cash distribution of $0.03 per share. This supplemental cash distribution will be paid out of Hercules Capital’s undistributed taxable income (taxable income in excess of distributions paid) as of September 30, 2019.

  • Business Wire

    Hercules Capital Declares Distribution of $0.32 per Share for the Third Quarter of 2019

    Hercules Capital, Inc. (HTGC) (“Hercules” or the “Company”), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a third quarter 2019 cash distribution of $0.32 per share. Hercules' Board of Directors maintains a variable distribution policy with the objective of distributing four quarterly distributions in an amount that approximates 90% to 100% of the Company’s taxable quarterly income or potential annual income for a particular year. In addition, during the year, the Company’s Board of Directors may choose to pay additional supplemental distributions, so that the Company may distribute approximately all its annual taxable income in the year it was earned, or it can elect to maintain the option to spill over the excess taxable income into the coming year for future distribution payments.

  • Business Wire

    Hercules Announces Date for Release of Third Quarter 2019 Financial Results and Conference Call

    Hercules Capital, Inc. , the largest and leading specialty financing provider to innovative venture growth stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its third quarter 2019 financial results conference call for Wednesday, October 30, 2019, at 2:00 p.m.

  • GlobeNewswire

    Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital

    Antares Pharma, Inc. (ATRS) (“Antares” or “the Company”) today announced that it has entered into an amendment to its existing loan and security agreement with Hercules Capital, Inc. (HTGC), (“Hercules”), to increase the available debt capital by $25 million for a term loan of up to $50 million. At the same time Antares also provided notice of the termination of the At-The-Market (“ATM”) equity offering facility which will be effective on July 6, 2019.

  • Business Wire

    Hercules Capital Announces Multiple Portfolio Company Achievements in Q2 2019

    Hercules Capital, Inc. , the largest and leading specialty financing provider to innovative venture growth stage companies backed by some of the leading U.S.

  • Business Wire

    Hercules Capital, Inc. Closes Public Offering of Common Stock Including Option to Purchase Additional Shares

    Hercules Capital, Inc. today announced that it has closed its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $12.64 per share.

  • Business Wire

    Hercules Capital, Inc. Prices Public Offering of Common Stock

    Hercules Capital, Inc. (HTGC) (“Hercules”) today announced that it has priced its public offering of 5,000,000 shares of its common stock at a public offering price of $12.64 per share for total gross proceeds of approximately $63.2 million. Hercules has also granted the underwriters an option to purchase up to an additional 750,000 shares of its common stock. Morgan Stanley, Wells Fargo Securities, and Keefe, Bruyette & Woods, A Stifel Company, are acting as joint book-running managers in this offering, and Compass Point and Wedbush Securities are acting as co-managers in this offering.

  • Business Wire

    Hercules Capital, Inc. Announces Public Offering of Common Stock

    Hercules Capital, Inc. (HTGC) (“Hercules”) today announced that it plans to make a public offering of 5,000,000 shares of its common stock. Hercules also plans to grant the underwriters for the offering an option to purchase up to an additional 750,000 shares of its common stock. Morgan Stanley, Wells Fargo Securities, and Keefe, Bruyette & Woods, A Stifel Company, are acting as joint book-running managers in this offering, and Compass Point and Wedbush Securities are acting as co-managers in this offering.

  • Business Wire

    Hercules Capital to Discuss 2019 Growth Opportunities at the B. Riley FBR Institutional Investor Conference

    Hercules Capital, Inc. , the largest and leading specialty finance provider to innovative, venture growth stage companies backed by some o

  • Business Wire

    Hercules Capital Appoints Two Senior Investment Professionals in New Leadership Roles

    Hercules Capital, Inc. (HTGC) (“Hercules” or the “Company”), the largest specialty financing provider to innovative venture growth stage companies backed by leading venture capital and private equity firms, today announced the promotions of R. Bryan Jadot to Head of Life Sciences Venture Lending and Steve Kuo to Head of Technology Venture Lending. Jadot and Kuo each served long-term tenures of more than 13 years at Hercules, respectively, and have made significant contributions to the growth of the Company’s debt and equity investment portfolio which stands at more than $2.1 billion today.

  • Business Wire

    Hercules Capital Announces Supplemental Cash Distribution of $0.01 per Share for the First Quarter of 2019

    Hercules Capital, Inc. (HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture growth stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a supplemental cash distribution of $0.01 per share. This supplemental cash distribution will be paid out of Hercules Capital’s undistributed taxable income (taxable income in excess of distributions paid) as of March 31, 2019.